Lead Product(s) : Pindolol
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Phase II
Sponsor : Mankind Pharma
Deal Size : $12.1 million
Deal Type : Financing
Details : ACM-001.1 (S-pindolol benzoate) targets multiple pathways that drive cachexia and has generated promising proof of concept Phase 2a clinical data in cachexia patients.
Product Name : ACM-001
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
April 01, 2023
Lead Product(s) : Pindolol
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase II
Sponsor : Mankind Pharma
Deal Size : $12.1 million
Deal Type : Financing
Lead Product(s) : Pindolol
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The spike-protein component of ACM-001 is modeled after the immune-evasive beta variant. In animal studies the clinical vaccine candidate was safe and generated a protective immune response against the beta-variant and ancestral form of SARS-2.
Product Name : ACM-001
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 29, 2022
Lead Product(s) : Pindolol
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pindolol
Therapeutic Area : Musculoskeletal
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : S-oxprenolol is the second in a new class of anabolic-catabolic transforming agents (ACTAs) under development by Actimed and this newest patent completes the global patent estate relating to the treatment of ALS with S-oxprenolol.
Product Name : ACM-001
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 13, 2021
Lead Product(s) : Pindolol
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pindolol
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : $3.4 million
Deal Type : Series B Financing
Actimed Therapeutics Successfully Closed of £2.5m Extended Seed B Funding Round
Details : The proceeds will allow Actimed to further advance the development of its lead compound, S-pindolol (ACM-001.1), for cancer cachexia, by performing a Pharmacokinetic (PK) and Pharmacodynamic (PD) study due to start later this year.
Product Name : ACM-001
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
October 06, 2021
Lead Product(s) : Pindolol
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : $3.4 million
Deal Type : Series B Financing
Reset All
